AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- The United States Patent Office has awarded a patent to the company’s immunotherapeutic PD1-Vaxx.
- The vaccine is being designed for patients with non-small cell lung cancer (NSCLC).
- The patent will expire in 2040.
Clinical-stage immuno-oncology company Imugene Limited (ASX: IMU) has secured a new patent by the United States Patent Office.
The patent is for the company’s first-in-class programmed death-1 (PD1) vaccine, PD1-Vaxx, which is being developed for the treatment of non-small cell lung cancer. The patent protects the matter composition and cancer treatment method of the vaccine to deliver a therapeutic antibody response against the PD1 checkpoint target.
Titled “HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF”, the patent will expire on 11 February 2040. The original expiry date of the patent was 28 March 2038, and the extended patent expiry includes 685 days of patent-term adjustment.
Overview of PD1-Vaxx
The B-cell activating immunotherapy is designed to interfere with PD-1/PD-L1 binding and interaction to treat tumours such as lung cancer. The immunotherapy produces an anticancer effect similar to immune checkpoint inhibitor monoclonal antibodies including Opdivo®, Keytruda®, and Tecentriq®.